EP0000074B1 - Neue Bispidinderivate, Verfahren zu deren Herstellung und Arzneimittel, welche diese enthalten - Google Patents
Neue Bispidinderivate, Verfahren zu deren Herstellung und Arzneimittel, welche diese enthalten Download PDFInfo
- Publication number
- EP0000074B1 EP0000074B1 EP78100147A EP78100147A EP0000074B1 EP 0000074 B1 EP0000074 B1 EP 0000074B1 EP 78100147 A EP78100147 A EP 78100147A EP 78100147 A EP78100147 A EP 78100147A EP 0000074 B1 EP0000074 B1 EP 0000074B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- bispidine
- benzyl
- denotes
- general formula
- derivatives
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
Definitions
- the invention also relates to medicaments which contain compounds of the general formula I and their salts with physiologically tolerable acids.
- physiologically acceptable acids are e.g. in question: hydrochloric acid, sulfuric acid, phosphoric acid, acetic acid, malonic acid, succinic acid, fumaric acid, maleic acid, citric acid, tartaric acid, lactic acid and diamidosulfonic acid.
- the reaction of the N-monobenzyl bispidine with the compounds II can be carried out, for example, with sodium hydride in dimethylformamide; Sodium hydroxide in water or ethanol; Sodium carbonate in butanol or amyl alcohol; Potassium carbonate in water, methanol, isopropanol, butanol, amyl alcohol, acetone, acetonitrile, toluene, dimethylformamide, dimethyl sulfoxide or tetrahydrofuran; Sodium methylate in methanol; Sodium isopropylate in isopropanol; Potassium tert-butoxide in tert-butanol, tetrahydrofuran or dimethyl sulfoxide; Sodium amide in toluene or xylene etc. be performed.
- the reaction with sodium hydride in dimethylformamide works best. It is usually carried out at room temperature.
- the Mannich reaction can be carried out in the usual way.
- Suitable solvents are e.g. Tetrahydrofuran, chloroform, methylene chloride and particularly good methanol, ethanol and isopropanol. Glacial acetic acid and hydrochloric acid are preferred as acid acids for the reaction.
- the formaldehyde can also be used as paraformaldehyde in the reaction. It is convenient to carry out the reaction at elevated temperatures, e.g. at the boiling points of the solvents used. The reduction of the keto compounds obtained in this way works best according to Kishner Wolff.
- the new compounds and their salts have good antiarrhythmic activity and low toxicity.
- the substances were administered orally to rats (strain: Sprague Dawley, weight: 200 to 250 g) 45 minutes before the start of thiobutabarbital anesthesia (100 mg / kg ip).
- Akonitin which was infused 60 minutes after substance administration, was used as the arrhythmia-producing substance (dosage rate 0.005 mg / kg per minute).
- arrhythmias occur after an average of 3.32 minutes, the onset of which can be delayed by antiarrhythmia depending on the dose.
- the ED 50% is the dose that increases the infusion time by 50% until arrhythmias occur.
- RW is the relative effect based on quinidine ⁇ 1.00.
- the maximum effect is that which is achieved when the maximum tolerated dose is applied.
- A% indicates the percentage by which the duration of the aconitine infusion can be extended.
- the dose at Toxic effect indicates the amount (mg / kg) at which the first toxic symptoms such as cyanosis or ECG changes occur.
- Q is the quotient of the toxic dose and the ED 50% .
- the new compounds and their salts have calcium antagonistic, antiphologistic and antiplatelet properties. They are well absorbed and should be administered orally and parenterally.
- the daily dose is about 1 to 20 mg / kg for oral administration and about 0.05 to 1.0 mg / kg for intravenous or intramuscular administration.
- For application e.g. Tablets, coated tablets and solutions.
- 165 ml of glacial acetic acid are mixed with 165 ml of methanol and, while stirring and cooling with ice, 65 g (0.33 mol) of 2,2-diphenylethylamine, 62.4 g (0.33 mol) of N-benzylpiperidone-4 and 24.6 in succession g (0.82 mol) of paraformaldehyde were added and the mixture was then refluxed for 3 hours with stirring.
- the glacial acetic acid and the methanol are largely removed in vacuo at 50 ° C., the residue is taken up in 1,000 ml of methylene chloride and, with stirring and ice cooling, 20% sodium hydroxide solution is added until the reaction is strongly alkaline.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hydrogenated Pyridines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19772726571 DE2726571A1 (de) | 1977-06-13 | 1977-06-13 | Neue bispidinderivate, verfahren zu deren herstellung und arzneimittel, welche diese enthalten |
DE2726571 | 1977-06-13 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0000074A1 EP0000074A1 (de) | 1978-12-20 |
EP0000074B1 true EP0000074B1 (de) | 1980-08-06 |
Family
ID=6011402
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP78100147A Expired EP0000074B1 (de) | 1977-06-13 | 1978-06-13 | Neue Bispidinderivate, Verfahren zu deren Herstellung und Arzneimittel, welche diese enthalten |
Country Status (7)
Country | Link |
---|---|
US (1) | US4183935A (fi) |
EP (1) | EP0000074B1 (fi) |
JP (1) | JPS5412398A (fi) |
AT (1) | AT363937B (fi) |
CA (1) | CA1105023A (fi) |
DE (2) | DE2726571A1 (fi) |
FI (1) | FI63403C (fi) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3226921A1 (de) * | 1981-07-20 | 1983-02-10 | Richter Gedeon Vegyészeti Gyár R.T., 1103 Budapest | Neue bicyclische verbindungen und verfahren zu ihrer herstellung |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5669785U (fi) * | 1979-11-01 | 1981-06-09 | ||
JPS5719791A (en) * | 1980-07-11 | 1982-02-02 | Tokyo Shibaura Electric Co | L.e.d. driving circuit |
DE3112055A1 (de) * | 1981-03-27 | 1982-10-07 | Basf Ag, 6700 Ludwigshafen | Bispidinderivate, ihre herstellung und diese enthaltende arzneimittel |
DE3234697A1 (de) * | 1982-09-18 | 1984-03-22 | Kali-Chemie Pharma Gmbh, 3000 Hannover | Neue diazabicyclo-(3,3,1)-nonane |
WO1989000158A1 (en) * | 1987-07-02 | 1989-01-12 | Pfizer Inc. | Bridged-diazabicycloalkyl quinolone carboxylic acids and esters |
DE3722134A1 (de) * | 1987-07-04 | 1989-01-19 | Kali Chemie Pharma Gmbh | 3-sulfonyl-3,7-diazabicyclo(3,3,1)nonan- verbindungen sowie verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
PT88381B (pt) * | 1987-09-09 | 1995-07-06 | Kali Chemie Pharma Gmbh | Processo para a preparacao de novos compostos 3,7-diazabiciclo{3,3,1} nonano, e de composicoes farmaceuticas que contem estes compostos |
DE3732094A1 (de) * | 1987-09-24 | 1989-04-06 | Basf Ag | Bispidinderivate als klasse iii-antiarrhythmika |
DE4019080A1 (de) * | 1990-06-15 | 1991-12-19 | Kali Chemie Pharma Gmbh | Neue 3,7-diazabicycolo (3,3,1)nonan-verbindungen enthaltende arzneimittel |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2428792A1 (de) * | 1974-06-14 | 1976-01-02 | Knoll Ag | Neue antiarrhythmika |
-
1977
- 1977-06-13 DE DE19772726571 patent/DE2726571A1/de not_active Withdrawn
-
1978
- 1978-06-08 JP JP6837578A patent/JPS5412398A/ja active Pending
- 1978-06-12 AT AT0426578A patent/AT363937B/de not_active IP Right Cessation
- 1978-06-12 FI FI781872A patent/FI63403C/fi not_active IP Right Cessation
- 1978-06-13 DE DE7878100147T patent/DE2860111D1/de not_active Expired
- 1978-06-13 EP EP78100147A patent/EP0000074B1/de not_active Expired
- 1978-06-13 US US05/915,119 patent/US4183935A/en not_active Expired - Lifetime
- 1978-06-13 CA CA305,369A patent/CA1105023A/en not_active Expired
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3226921A1 (de) * | 1981-07-20 | 1983-02-10 | Richter Gedeon Vegyészeti Gyár R.T., 1103 Budapest | Neue bicyclische verbindungen und verfahren zu ihrer herstellung |
Also Published As
Publication number | Publication date |
---|---|
CA1105023A (en) | 1981-07-14 |
FI63403C (fi) | 1983-06-10 |
FI63403B (fi) | 1983-02-28 |
FI781872A (fi) | 1978-12-14 |
AT363937B (de) | 1981-09-10 |
DE2860111D1 (en) | 1980-11-27 |
EP0000074A1 (de) | 1978-12-20 |
JPS5412398A (en) | 1979-01-30 |
ATA426578A (de) | 1981-02-15 |
US4183935A (en) | 1980-01-15 |
DE2726571A1 (de) | 1978-12-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE2658544C2 (de) | Carbostyrilderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel | |
DE19744027A1 (de) | Substituierte Pyrazolo[3,4-b]pyridine, ihre Herstellung und Verwendung in Arzneimitteln | |
DE1545912A1 (de) | Verfahren zur Herstellung von Perhydro-1,2,4-thiadiazindioxyden | |
DE2929777C2 (fi) | ||
DE1958918A1 (de) | Chemische Verfahren und Produkte | |
EP0000074B1 (de) | Neue Bispidinderivate, Verfahren zu deren Herstellung und Arzneimittel, welche diese enthalten | |
DE3114239C2 (de) | N↑4↑-Carbamoylpiperazinpropanolderivate, Verfahren zu ihrer Herstellung und pharmazeutisches Mittel | |
DE2604748A1 (de) | Aminoderivate von imidazo(4,5-b) pyridinen | |
DE2319278A1 (de) | Diuretisches und antihypertensives mittel | |
EP0054872B1 (de) | 3,4-Bis-substituierte 1,2,5-Oxadiazol-2-oxide, Verfahren zu ihrer Herstellung, und sie enthaltende pharmazeutische Zubereitungen | |
DE1914571A1 (de) | L-3-Hydroxy-6-oxomorphinan-Verbindungen und ihre Herstellung | |
DE1445950C3 (de) | 2,6-Bis-(hydroxymethyl)-pyridindicarbamat-derivate und Verfahren zu ihrer Herstellung | |
DE2000030C3 (de) | 3-Alkoxy-und 3-Phenoxy-2-(diphenylhydroxy)methyl-propylamine und diese enthaltende Arzneimittel | |
DD153368A5 (de) | Verfahren zur herstellung von tetrahydrochinolinderivaten | |
DE2427272B2 (de) | (5), Verfahren zur Herstellung sowie dieses enthaltende Arzneimittel | |
DE2322073A1 (de) | Neue aminoderivate von pyridopyridazincarbonsaeureestern und -carbonsaeuren mit ihren salzen | |
DE2410201A1 (de) | 6-substituierte 3-carbaethoxyhydrazinopyridazine beziehungsweise ihre salze sowie ihre verwendung und verfahren zur herstellung derselben | |
DE2015731C3 (de) | Azamorphinanverbindungen, Verfahren zu ihrer Herstellung und pharmazeutische Zubereitungen | |
DE2356005A1 (de) | Neue 7-amino-imidazo eckige klammer auf 1,2-a eckige klammer zu pyrimidine, diese enthaltende arzneimittel sowie verfahren zu deren herstellung | |
AT363938B (de) | Verfahren zur herstellung von neuen bispidinderivaten und deren salzen | |
DE2446495A1 (de) | Neue pyrazolo(3,4-b)thieno(2,3-d) pyridin-2-carboxylsaeuren und -saeureester | |
DE2319281A1 (de) | Diuretisches und antihypertensives mittel | |
DE2728315A1 (de) | Glycerin-1,2-bis-(aminoalkylaether), verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneipraeparate | |
EP0003298A2 (de) | 4-Hydroxy-2-benzimidazolin-thion-Derivate, Verfahren zu deren Herstellung sowie diese Verbindungen enthaltende Arzneimittel | |
CH662116A5 (de) | Kondensierte as-triazinium-derivate. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): BE CH DE FR GB NL SE |
|
17P | Request for examination filed | ||
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): BE CH DE FR GB NL SE |
|
REF | Corresponds to: |
Ref document number: 2860111 Country of ref document: DE Date of ref document: 19801127 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 19820630 Year of fee payment: 5 Ref country code: DE Payment date: 19820630 Year of fee payment: 5 Ref country code: CH Payment date: 19820630 Year of fee payment: 5 Ref country code: BE Payment date: 19820630 Year of fee payment: 5 Ref country code: SE Payment date: 19820630 Year of fee payment: 5 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 19820705 Year of fee payment: 5 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Effective date: 19830429 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Effective date: 19830613 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Effective date: 19830614 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CH Effective date: 19830630 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Effective date: 19840101 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee | ||
NLV4 | Nl: lapsed or anulled due to non-payment of the annual fee | ||
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19840229 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Effective date: 19881117 |
|
EUG | Se: european patent has lapsed |
Ref document number: 78100147.4 Effective date: 19850610 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |